Thymosin α-1 vs VIP.

Thymosin alpha-1 (Tα1, international nonproprietary name thymalfasin; brand name Zadaxin) is a synthetic 28-amino-acid acetylated peptide identical to a naturally occurring fragment derived from prothymosin alpha, a protein produced in the thymus. It belongs to the thymosin family of thymic-derived peptides and is one of the most clinically studied immunomodulatory peptides, marketed as a prescription immune modulator in numerous countries outside the United States.

VIP (vasoactive intestinal peptide, also called vasoactive intestinal polypeptide) is a 28-amino-acid neuropeptide first isolated from porcine intestine in the early 1970s. It is highly conserved across mammals and belongs to the secretin/glucagon peptide superfamily, sharing close homology with PACAP (pituitary adenylate cyclase-activating polypeptide). It is widely distributed in the central and peripheral nervous systems and in the gut, and is notably enriched in lung tissue. The synthetic form used in human trials is known as aviptadil.

Tα1 is an immune modulator rather than a simple immune stimulant: it acts largely through Toll-like receptors, principally TLR2 and TLR9, on dendritic cells, monocytes/macrophages, and other antigen-presenting cells. Downstream MyD88-dependent signaling promotes dendritic cell maturation, biases naive T cells toward Th1 differentiation, augments natural killer cell and cytotoxic T-cell activity, and can modulate regulatory pathways including indoleamine 2,3-dioxygenase. In settings of immune exhaustion or sepsis-associated immunoparalysis, the proposed benefit is restoration of T-lymphocyte numbers and function (e.g., raising depleted CD4+/CD8+ counts and reducing markers of T-cell exhaustion) rather than broad immune activation.

VIP signals through two class B G-protein-coupled receptors, VPAC1 and VPAC2, both of which bind VIP and PACAP with high affinity (a related receptor, PAC1, is PACAP-selective). Receptor activation couples primarily to adenylate cyclase, raising intracellular cAMP, with secondary coupling to phospholipase C in some contexts. Downstream effects include smooth-muscle relaxation and vasodilation, bronchodilation, stimulation of exocrine and electrolyte secretion, glucose-dependent insulin secretion (largely via VPAC2), and broad immunomodulatory/anti-inflammatory actions that shift cytokine balance away from pro-inflammatory mediators. In the lung, VIP receptors are concentrated on alveolar type II cells, which is part of the rationale for studying it in acute lung injury.

Human evidence is most developed in chronic hepatitis B and as an adjunct in sepsis, but is mixed and often comes from China-based studies of variable quality. The largest dedicated sepsis trial, ETASS (Wu et al., Critical Care 2013, a multicenter single-blind RCT of 361 patients with severe sepsis), found a reduction in 28-day all-cause mortality that did not reach statistical significance, so its primary endpoint was formally negative; subsequent systematic reviews (e.g., Liu et al., BMC Infect Dis 2016) noted possible mortality benefit but flagged small sample sizes, heterogeneity, and risk of bias. In COVID-19, the widely cited Liu et al. (Clin Infect Dis 2020) report associating Tα1 with lower mortality was a retrospective review of only 76 severe cases, not a randomized trial, and cannot establish efficacy. For hepatitis B, meta-analyses (e.g., entecavir plus Tα1 in HBV-related cirrhosis, BMC Gastroenterol 2020) suggest possible adjunctive benefit on virologic and immune endpoints but again rest on heterogeneous trials; high-quality Western regulatory trials have not confirmed a clear benefit. Much of the broader "immune-restoring" and anti-cancer rationale remains preclinical or mechanistic.

Human evidence is mixed and, for most systemic indications, limited. The strongest, most rigorous human data come from TESICO (ACTIV-3b), a randomized, placebo-controlled trial of intravenous aviptadil in COVID-19-associated hypoxaemic respiratory failure published in Lancet Respiratory Medicine (2023); it enrolled ~471 randomized participants and was stopped for futility, finding no improvement in clinical outcomes versus placebo. The earlier enthusiasm rested largely on small open-label series and preclinical/animal models of acute lung injury and cytokine suppression, which did not translate into proven benefit in the controlled setting. The best-established human use is local, not systemic: aviptadil combined with phentolamine (Invicorp) is an approved intracavernosal injection for erectile dysfunction in several countries. VIP has also held orphan-drug designations for pulmonary hypertension and sarcoidosis, but those indications lack confirmatory pivotal trial evidence.

Across decades of clinical use as thymalfasin, Tα1 has generally been reported as well tolerated, with injection-site reactions among the more commonly noted effects; it is a peptide given by injection in studied settings. Because its action is immunomodulatory, theoretical and context-dependent concerns include effects in autoimmune disease, transplant recipients, or other immune-sensitive populations, and immunogenicity is one reason regulators have scrutinized compounded versions. Importantly, much safety data comes from regulated pharmaceutical product used under medical supervision; the purity, identity, and safety of research-grade or compounded "gray market" material are not assured, and long-term safety outside approved indications is not well characterized.

As an endogenous vasodilator, systemic VIP/aviptadil can cause hypotension, flushing, and diarrhea, and intravenous infusion has been associated with these effects in trials. Excess endogenous VIP, as seen in VIPoma tumors, produces severe secretory (watery) diarrhea, hypokalemia, and dehydration, illustrating its potent secretory pharmacology. For intracavernosal use, the combination product is reported to carry low rates of penile pain and priapism relative to some other injectables. Long-term safety of systemic administration is not well characterized, and the controlled COVID-19 data did not establish a net clinical benefit; safety beyond the studied settings remains uncertain.

Thymalfasin (Zadaxin) is approved and marketed as a prescription drug in roughly 30-plus countries (including China, Italy, and parts of Asia, Latin America, and the Middle East), chiefly for chronic hepatitis B and as an immune adjunct, but it is NOT approved by the US FDA or centrally by the EMA; in the US it has held orphan-drug designations and been studied investigationally. In US compounding, FDA placed thymosin alpha-1 in Category 2 of the interim 503A bulk substances list in 2023 (citing safety/data concerns), and in 2024 it was removed from Category 2 after its nomination was withdrawn, leaving it without a clear compounding pathway.

VIP itself is not an FDA-approved drug; intravenous aviptadil is investigational in the United States and was studied under FDA mechanisms including orphan-drug designations (pulmonary hypertension, sarcoidosis) and emergency COVID-19 trials. The aviptadil/phentolamine combination (Invicorp) is approved for erectile dysfunction in several countries including the UK, Denmark, and New Zealand, but not broadly in the US.